利民股份(002734.SZ)与昶科生物签署战略合作协议
格隆汇10月28日丨利民股份(002734.SZ)公布,2024年10月21日,公司与厦门昶科生物工程有限公司(以下简称"昶科生物")签署了《战略合作协议》(以下简称"本协议"或"协议"),双方将共同致力于发展以合成生物学技术、噬菌体技术为底层技术的噬菌体生物农药,创制研发、推广应用新型农用噬菌体生物产品。
根据协议,双方共同创制开发新型基于噬菌体的生物农药;噬菌体的生物农药登记证申报;合作销售噬菌体、天然虾青素的微生物菌剂产品。根据双方的未来发展战略和资本规划,可择机开展共同投资新设合作项目等方面的合作,加强双方的资源整合和战略协同。
此协议的签署,是公司"一主两辅"战略的落地实措。合作开展后,对在合成生物学方面持续发力、丰富公司产品结构、提升公司核心竞争力和持续发展能力有着构建底层基础、实现弯道超车和推动行稳致远的深厚意义。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.